Georgia's Online Cancer Information Center


back

Ovarian Cancer Clinical Trials in Georgia

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.
Cancer Type = Ovarian Cancer
Cancer Type = Ovarian Cancer
NCI ID Cancer Type Trial Name
There are currently 31 active Ovarian Cancer clinical trials in Georgia.
NCI ID Cancer Type Trial Name
1.
A Beta-only IL-2 ImmunoTherapY Study
Cancer Type
Bile Duct Cancer, Bladder Cancer, Cervical Cancer, Colon/Rectal Cancer, Gallbladder Cancer, Melanoma, Ovarian Cancer, Sarcoma, Stomach/ Gastric Cancer
NCT ID
NCT05086692
Protocol IDs
MDNA11-01
NCI-2022-02678
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
2.
A Study Combining the Peposertib (M3814) Pill with Standard Chemotherapy in Patients with Ovarian Cancer with an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer
Cancer Type
Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer
NCT ID
NCT04092270
Protocol IDs
10324
10324
NCI-2019-06123
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
3.
A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies
Cancer Type
Bladder Cancer, Breast Cancer, Colon/Rectal Cancer, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Ovarian Cancer, Unknown Primary
NCT ID
NCT06120075
Protocol IDs
ARC-27
NCI-2024-03901
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
4.
NCORP Trial
A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma
Cancer Type
Ovarian Cancer, Solid Tumor, Unknown Primary, Uterine Cancer
NCT ID
NCT05548296
Protocol IDs
ACR-368-201 (GOG 3082)
NCI-2022-10629
Treatment Sites (2)
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
Winship Cancer Institute of Emory University
Atlanta
5.
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
Cancer Type
Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer
NCT ID
NCT06072781
Protocol IDs
VS-6766-301
NCI-2024-00300
ENGOT-ov81
GOG-3097
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
6.
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
Cancer Type
Esophogeal Cancer, Gynecologic Cancers, Lung Cancer, Ovarian Cancer, Prostate Cancer
NCT ID
NCT06238479
Protocol IDs
LOXO-ENC-23001
NCI-2024-02612
2023-509867-26-00
J5A-OX-JZWA
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
7.
NCORP Trial
A Study to Compare Two Surgical Procedures in Individuals with BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Cancer Type
Ovarian Cancer
NCT ID
NCT04251052
Protocol IDs
NRG-CC008
NRG-CC008
NRG-CC008
NCI-2019-07791
Treatment Sites (5)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
Summit Cancer Care at the Nancy N. Lewis and J.C. Lewis Cancer & Research Pavilion
Savannah
8.
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRa)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Cancer Type
Gynecologic Cancers, Lung Cancer, Ovarian Cancer, Primary Peritoneal Cancer, Solid Tumor
NCT ID
NCT04300556
Protocol IDs
MORAb-202-G000-201
NCI-2020-06147
2019-003600-12
Treatment Sites (1)
Georgia Cancer Center at Augusta University
Augusta
9.
NCORP Trial
AOA-PRT-0001: Collection and Banking of Blood Samples for the Study of Female Gynecological Diseases
Cancer Type
Gynecologic Cancers, Ovarian Cancer
NCT ID
Protocol IDs
AOA-PRT-001
Treatment Sites (1)
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
10.
NCORP Trial
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Cancer Type
Bladder Cancer, Breast Cancer, Cervical Cancer, Colon/Rectal Cancer, Esophogeal Cancer, Head and Neck Cancer, Leukemia, Lung Cancer, Lymphoma, Multiple Myeloma, Ovarian Cancer, Prostate Cancer , Sarcoma, Solid Tumor, Stomach/ Gastric Cancer, Thyroid Cancer
NCT ID
NCT05366881
Protocol IDs
Adela-EDMRD-001
NCI-2022-04272
Treatment Sites (1)
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
11.
Dose-Escalation and Dose-Expansion Study of ZX-4081 in Patients With Advanced Solid Tumors
Cancer Type
Breast Cancer, Colon/Rectal Cancer, Liver Cancer / Hepatoblastoma, Lung Cancer, Melanoma, Ovarian Cancer, Unknown Primary
NCT ID
NCT05118841
Protocol IDs
ZX-4081
NCI-2022-02249
12.
First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)
Cancer Type
Breast Cancer, Cervical Cancer, Colon/Rectal Cancer, Esophogeal Cancer, Lung Cancer, Ovarian Cancer, Stomach/ Gastric Cancer
NCT ID
NCT03401385
Protocol IDs
DS1062-A-J101
NCI-2018-01200
173812
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
13.
Genetic Testing in African Americans (GTM-I)
Cancer Type
Endometrial Cancer, Ovarian Cancer
NCT ID
NCT05591131
Protocol IDs
GTM-I
Treatment Sites (1)
Georgia Cancer Center at Augusta University
Augusta
14.
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Cancer Type
Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer, Unknown Primary
NCT ID
NCT05659381
Protocol IDs
GOG-3068
NCI-2023-08813
217908
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
15.
NCORP Trial
Letrozole with or without Paclitaxel and Carboplatin in Treating Patients with Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Cancer Type
Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer, Unknown Primary
NCT ID
NCT04095364
Protocol IDs
NRG-GY019
NRG-GY019
NCI-2019-01460
Treatment Sites (4)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
16.
Message-Based Communication Outreach Intervention in Engaging Ovarian Cancer Survivors and Relatives to Consider Genetic Screening Services
Cancer Type
Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer, Unknown Primary
NCT ID
NCT04927013
Protocol IDs
RSPH4984-20
NCI-2020-02281
STUDY00000224
17.
NCORP Trial
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA)
Cancer Type
Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer, Unknown Primary
NCT ID
NCT05445778
Protocol IDs
IMGN853-0421
NCI-2023-00369
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
18.
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Cancer Type
Breast Cancer, Cervical Cancer, Esophogeal Cancer, Lung Cancer, Ovarian Cancer, Stomach/ Gastric Cancer
NCT ID
NCT06293898
Protocol IDs
BL-M07D1-ST-101
NCI-2024-07363
Treatment Sites (1)
Georgia Cancer Center at Augusta University
Augusta
19.
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients with Advanced Cancer
Cancer Type
Breast Cancer, Ovarian Cancer
NCT ID
NCT05735080
Protocol IDs
INX-315-01
NCI-2023-04176
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
20.
NCORP Trial
REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1
Cancer Type
Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer, Unknown Primary
NCT ID
NCT05870748
Protocol IDs
STRO-002-GM3
NCI-2023-04597
APGOT-OV9
ENGOT-OV79
GEICO-134-O
GOG-3086
Treatment Sites (2)
Georgia Cancer Center at Augusta University
Augusta
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
21.
NCORP Trial
Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer
Cancer Type
Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer, Unknown Primary
NCT ID
NCT05257408
Protocol IDs
CORT125134-556
NCI-2022-07960
GOG-3073
Treatment Sites (2)
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
Winship Cancer Institute of Emory University
Atlanta
22.
Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer
Cancer Type
Ovarian Cancer
NCT ID
NCT05998135
Protocol IDs
WINSHIP5782-22
NCI-2023-03479
STUDY00005363
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
23.
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
Cancer Type
Breast Cancer, Colon/Rectal Cancer, Head and Neck Cancer, Liver Cancer / Hepatoblastoma, Lung Cancer, Melanoma, Ovarian Cancer, Sarcoma, Stomach/ Gastric Cancer
NCT ID
NCT04140526
Protocol IDs
ONC-392-001
R44CA250824-01
NCI-2020-06149
20193108
4R44CA250824-02
24.
STK-012 Monotherapy and in Combination Therapy in Patients with Solid Tumors
Cancer Type
Head and Neck Cancer, Kidney Cancer, Lung Cancer, Melanoma, Ovarian Cancer, Solid Tumor, Unknown Primary
NCT ID
NCT05098132
Protocol IDs
STK-012-101
NCI-2022-00633
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
25.
Study of INCB123667 in Subjects With Advanced Solid Tumors
Cancer Type
Esophogeal Cancer, Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer, Stomach/ Gastric Cancer
NCT ID
NCT05238922
Protocol IDs
INCB 123667-101
NCI-2022-03370
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
26.
NCORP Trial
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DO-01)
Cancer Type
Ovarian Cancer
NCT ID
NCT06819007
Protocol IDs
DS8201-772
ENGOT-ov89 ( Other Grant/Funding Number ) (OTHER_G
GEICO144-O ( Other Grant/Funding Number ) (OTHER_G
GOG-3112 ( Other Grant/Funding Number ) (OTHER_GRA
Treatment Sites (1)
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
27.
Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors
Cancer Type
Colon/Rectal Cancer, Lung Cancer, Ovarian Cancer
NCT ID
NCT02715284
Protocol IDs
4010-01-001
NCI-2016-01910
Treatment Sites (1)
Georgia Cancer Center at Augusta University
Augusta
28.
Targeted Therapy Directed by Genetic Testing in Treating Patients with Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Cancer Type
Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer
NCT ID
NCT05564377
Protocol IDs
EAY191
EAY191
NCI-2022-06842
29.
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Cancer Type
Brain Tumor, Colon/Rectal Cancer, Liver Cancer / Hepatoblastoma, Melanoma, Neuroblastoma, Non-Hodgkin Lymphoma, Ovarian Cancer, Sarcoma, Uterine Cancer, Wilms Tumor
NCT ID
NCT04851119
Protocol IDs
PEPN2011
PEPN2011
NCI-2021-02852
30.
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
Cancer Type
Ovarian Cancer, Uterine Cancer
NCT ID
NCT05950464
Protocol IDs
NRG-GY031
NRG-GY031
NCI-2023-03408
Treatment Sites (1)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
31.
Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer
Cancer Type
Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer, Unknown Primary
NCT ID
NCT05276973
Protocol IDs
NRG-GY027
NRG-GY027
NCI-2022-01930
Treatment Sites (1)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
About Us Research Resources & Education Screening & Genetics Clinical Trials & Providers Cancer Navigators Survivorship Media, News & Events Contact Us Donate Take Our Survey Link to Us

Research

Screening & Genetics

Find Cancer Care

Survivorship

About Georgia CORE

Education & Resources

Media, News & Events

Patient Navigation

Georgia CORE

 

Georgia CORE bridges the gap between groundbreaking research, educational outreach, and effective advocacy to transform the landscape of cancer care for all Georgians.